Aziyo Biologics Executives
AZYODelisted Stock | USD 2.44 0.00 0.00% |
Aziyo Biologics employs about 151 people. The company is managed by 9 executives with a total tenure of roughly 353 years, averaging almost 39.0 years of service per executive, having 16.78 employees per reported executive. Analysis of Aziyo Biologics' management performance can provide insight into the firm performance.
Aziyo |
Aziyo Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2875) % which means that it has lost $0.2875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7514) %, meaning that it created substantial loss on money invested by shareholders. Aziyo Biologics' management efficiency ratios could be used to measure how well Aziyo Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Aziyo Biologics Workforce Comparison
Aziyo Biologics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 10,048. Aziyo Biologics claims roughly 151 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.7) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.5) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.5. Aziyo Biologics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aziyo Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aziyo Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aziyo Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mills C Randal over a year ago Exercise or conversion by Mills C Randal of 22474 shares of Aziyo BiologicsInc subject to Rule 16b-3 | ||
Highcape Capital Lp over a year ago Acquisition by Highcape Capital Lp of 37500 shares of Aziyo BiologicsInc subject to Rule 16b-3 | ||
Mills C Randal over a year ago Exercise or conversion by Mills C Randal of 44947 shares of Aziyo BiologicsInc subject to Rule 16b-3 | ||
Thomas Englese over a year ago Exercise or conversion by Thomas Englese of 937 shares of Aziyo BiologicsInc subject to Rule 16b-3 |
Aziyo Biologics Notable Stakeholders
An Aziyo Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aziyo Biologics often face trade-offs trying to please all of them. Aziyo Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aziyo Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Erica Elchin | VP Operations | Profile | |
Matthew Ferguson | Chief Officer | Profile | |
Randal Mills | Pres CoFounder | Profile | |
MS MBA | Ex Chairman | Profile | |
Michelle Williams | Chief Officer | Profile | |
Jeffry Hamet | Treasurer Fin | Profile | |
Sonali Fonseca | Head Buses | Profile | |
Courtney Guyer | VP Marketing | Profile | |
Thomas Englese | Chief Officer | Profile |
About Aziyo Biologics Management Performance
The success or failure of an entity such as Aziyo Biologics often depends on how effective the management is. Aziyo Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aziyo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aziyo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic devicecardiovascular, orthopedicspinal repair, and soft tissue reconstruction markets. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland. Aziyo Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 162 people.
Aziyo Biologics Workforce Analysis
Traditionally, organizations such as Aziyo Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aziyo Biologics within its industry.Aziyo Biologics Manpower Efficiency
Return on Aziyo Biologics Manpower
Revenue Per Employee | 325.7K | |
Revenue Per Executive | 5.5M | |
Net Loss Per Employee | 217.9K | |
Net Loss Per Executive | 3.7M | |
Working Capital Per Employee | 53.5K | |
Working Capital Per Executive | 898.2K |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Aziyo Stock
If you are still planning to invest in Aziyo Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aziyo Biologics' history and understand the potential risks before investing.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |